Fracture risk assessment in clinical practice: T-scores, FRAX, and beyond

被引：3
作者：
Lewiecki E.M. [1 ]
机构：
[1] New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106
来源：
Clinical Reviews in Bone and Mineral Metabolism | 2010年 / 8卷 / 3期
关键词：
BMD; Bone mineral density; Clinical risk factors; FRAX; Osteoporosis; Prevention; T-score; Treatment;
D O I：
10.1007/s12018-009-9054-6
中图分类号：
学科分类号：
摘要：
Assessment of fracture risk is a key component in the evaluation of skeletal health and a critical step in determining whether to initiate pharmacological therapy to reduce fracture risk. The identification of high risk patients allows clinicians to direct limited healthcare resources to those who are most likely to benefit. Bone mineral density (BMD) and clinical risk factors (CRFs) for fracture predict fracture risk better than BMD or CRFs alone. Dual-energy X-ray absorptiometry (DXA) is a technology for the measurement of BMD to diagnose osteoporosis, assess fracture risk, and monitor the BMD response to therapy. Validated CRFs and femoral neck BMD by DXA, when available, provide the input for the World Health Organization fracture risk assessment tool (FRAX) to estimate the 10-year probability of fracture in untreated patients. Economic models have included FRAX in calculations to estimate when pharmacological intervention is likely to be cost-effective in reducing fracture risk. Cost-effectiveness is one of many factors to consider in making treatment decisions. This is a review of the benefits and limitations of BMD testing, CRFs, and FRAX in the management of patients in clinical practice. © 2009 Humana Press Inc.
引用
收藏
页码：101 / 112
页数：11
相关论文
共 107 条
  • [1] Klibanski A., Adams-Campbell L., Bassford T., Blair S.N., Boden S.D., Dickersin K., Et al., Osteoporosis prevention, diagnosis, and therapy, JAMA, 285, 6, pp. 785-795, (2001)
  • [2] Kanis J.A., On behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level, Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, (2007)
  • [3] Clinician's Guide to Prevention and Treatment of Osteoporosis, (2008)
  • [4] Bone Health and Osteoporosis: A Report of the Surgeon General, (2004)
  • [5] Cooper C., Johnell O., Lips P., Melton L.J., Kanis J.A., The global burden of vertebral fractures (abstract), J Bone Miner Res, 17, SUPPL. 1, (2002)
  • [6] Johnell O., Kanis J.A., An estimate of the worldwide prevalence, mortality and disability associated with hip fracture, Osteoporos Int, 15, 11, pp. 897-902, (2004)
  • [7] Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., Eisman J.A., Mortality after all major types of osteoporotic fracture in men and women: An observational study, Lancet, 353, 9156, pp. 878-882, (1999)
  • [8] Cooper C., The crippling consequences of fractures and their impact on quality of life, Am J Med, 103, 2 A, (1997)
  • [9] Silverman S.L., The clinical consequences of vertebral compression fracture, Bone, 13, SUPPL. 2, (1992)
  • [10] Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., Tosteson A., Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025, J Bone Miner Res, 22, 3, pp. 465-475, (2007)
12345678910